Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
FUZE
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
- NCT03834220 ↗
- Terminated
- Debiopharm International SA
- Focused
We haven't built an HCP commentary report on FUZE yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on FUZE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Solid Tumor
- Interventions
- Debio 1347
- Arms
- Cohort 1: Debio 1347 (Biliary Tract Cancer) · Experimental
- Cohort 2: Debio 1347 (Urothelial Cancer) · Experimental
- Cohort 3: Debio 1347 (All Other Solid Tumor Histologies) · Experimental
- Enrollment
- 63
- Primary outcomes
- Objective Response Rate (ORR) as Centrally Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Criteria
- Sponsor
- Debiopharm International SA with Caris Life Sciences, Optimal Research (Just In Time sites)
- Start
- Mar 22, 2019
- Primary completion
- Dec 31, 2020
- Results posted
- Yes
- Registry record
- NCT03834220 · updated Feb 7, 2024